跳至主要内容
临床试验/NCT06662474
NCT06662474尚未招募不适用

Evaluation of Cognitive Dysfunction in Patients with Breast Cancer Undergoing Systemic Therapy

Grigore T. Popa University of Medicine and Pharmacy0 个研究点目标入组 120 人开始时间: 2024年11月1日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
120
主要终点
presence of cognitive decline in breast cancer patients receiving systemic treatments

研究概览

简要总结

The investigators aim is to conduct a prospective study with three arms, involving non-metastatic breast cancer patients who underwent chemotherapy as part of their treatment and were on a form of hormone therapy at the time of study inclusion. The trial consists of identifying the presence of cognitive decline and following up on methods of preventing its accentuation. The goal of this clinical trial is to assess if psychoeducation and cognitive stimulation work to decrease the intensity of cognitive impairment. It aims to answer the following main questions:

  • The implementation of such interventions improves both the dysfunction quantified by objective tests but also the individual's perception of it.
  • The implementation changes the patients' quality of life. Researchers will compare three study groups, each with instructions to complete one of the related 12-week programs, to see if there are any changes.

Depending on the group in which the patient was randomly assigned, the interventions are :

  • First group - will engage in exercises like sudoku, word games, and painting by numbers for 30 minutes per day, three days per week, for a duration of 12 weeks
  • the second group will engage in exercises like sudoku, word games, and painting by numbers for 30 minutes per day, three days per week, for a duration of 12 weeks and also hold open group meetings for psychoeducation (1 meeting every 2 weeks, 6 meetings in total).
  • Group 3 is considered a control group, consisting of people who maintained their lifestyle up until their inclusion in the study without following additional measures

详细描述

The trial consists of identifying the presence of cognitive decline and following up on methods of preventing its accentuation through psychoeducation and cognitive stimulation. The trial includes longitudinal assessments of some subjective perception markers and objective assessments of cognitive decline. Furthermore, the study will delve into the dynamics of these markers, revealing alterations in the psycho-affective state. The study aims to assess the impact of interventions on the cognitive decline associated with cancer and its treatment, as well as the role they can play in improving breast cancer patients' quality of life.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • female patients aged 18 years or older
  • histologically confirmed treated invasive non-metastatic HR positive
  • provided written informed consent
  • (ECOG) performance status 0 -2
  • adequate hematologic functions
  • the patients must have completed the treatment (surgery or chemotherapy) for a minimum of 6 months and a maximum of 3 years before enrolling in the study
  • patients who received chemotherapy for at least 3 months, including both dose-dense regimens and those administered every 3 weeks, as part of their disease treatment.
  • patients are considered eligible for study continuation if, in 1 month of screening procedures, the tests to identify depression and severe anxiety do not indicate a severe status for them.

排除标准

  • history of neoplasia other than breast cancer
  • brain metastases
  • acute neurological diseases, neuro-degenerative or major psychiatric conditions such as stroke, autism, ADHD, Alzheimer's disease, Parkinson's disease, dementia, obsessive-compulsive disorder, post-traumatic stress disorder, schizophrenia, and those with a history of craniocerebral trauma
  • associated pathologies who may receive any form of treatment
  • the administration of psychotropic or pain medications in the II and III categories
  • (ECOG) ≧3
  • laboratory tests that contraindicate the administration of active oncological treatment

结局指标

主要结局

presence of cognitive decline in breast cancer patients receiving systemic treatments

时间窗: before initiating interventions

using objective tests

rate of cognitive decline delay among those who implement prophylactic measures

时间窗: from the moment the intervention was initiated until 6 months after the intervention

using objective tests

次要结局

  • quality of life(from the moment the intervention was initiated until 6 months after the intervention)
  • psycho-emotional status - state of coping assessment(from the moment the intervention was initiated until 6 months after the intervention)
  • psycho-emotional status - assessment of disturbance(from the moment the intervention was initiated until 6 months after the intervention)

研究者

发起方
Grigore T. Popa University of Medicine and Pharmacy
申办方类型
Other
责任方
Principal Investigator
主要研究者

Diana Ioana Boboc

Medical Oncologist, PhD Student, Investigator in Clinical Trials

Grigore T. Popa University of Medicine and Pharmacy

相似试验